Cargando…
Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease
Progression of autosomal dominant polycystic kidney disease (ADPKD) is modified by metabolic defects and obesity. Indeed, reduced food intake slows cyst growth in preclinical rodent studies. Here, we demonstrate the feasibility of daily caloric restriction (DCR) and intermittent fasting (IMF) in a c...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760407/ https://www.ncbi.nlm.nih.gov/pubmed/35059607 http://dx.doi.org/10.1016/j.isci.2021.103697 |
_version_ | 1784633312891895808 |
---|---|
author | Hopp, Katharina Catenacci, Victoria A. Dwivedi, Nidhi Kline, Timothy L. Wang, Wei You, Zhiying Nguyen, Dustin T. Bing, Kristen Poudyal, Bhavya Johnson, Ginger C. Jackman, Matthew R. Miller, Marsha Steele, Cortney N. Serkova, Natalie J. MacLean, Paul S. Nemenoff, Raphael A. Gitomer, Berenice Chonchol, Michel Nowak, Kristen L. |
author_facet | Hopp, Katharina Catenacci, Victoria A. Dwivedi, Nidhi Kline, Timothy L. Wang, Wei You, Zhiying Nguyen, Dustin T. Bing, Kristen Poudyal, Bhavya Johnson, Ginger C. Jackman, Matthew R. Miller, Marsha Steele, Cortney N. Serkova, Natalie J. MacLean, Paul S. Nemenoff, Raphael A. Gitomer, Berenice Chonchol, Michel Nowak, Kristen L. |
author_sort | Hopp, Katharina |
collection | PubMed |
description | Progression of autosomal dominant polycystic kidney disease (ADPKD) is modified by metabolic defects and obesity. Indeed, reduced food intake slows cyst growth in preclinical rodent studies. Here, we demonstrate the feasibility of daily caloric restriction (DCR) and intermittent fasting (IMF) in a cohort of overweight or obese patients with ADPKD. Clinically significant weight loss occurred with both DCR and IMF; however, weight loss was greater and adherence and tolerability were better with DCR. Further, slowed kidney growth correlated with body weight and visceral adiposity loss independent of dietary regimen. Similarly, we compared the therapeutic efficacy of DCR, IMF, and time restricted feeding (TRF) using an orthologous ADPKD mouse model. Only ADPKD animals on DCR lost significant weight and showed slowed cyst growth compared to ad libitum, IMF, or TRF feeding. Collectively, this supports therapeutic feasibility of caloric restriction in ADPKD, with potential efficacy benefits driven by weight loss. |
format | Online Article Text |
id | pubmed-8760407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-87604072022-01-19 Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease Hopp, Katharina Catenacci, Victoria A. Dwivedi, Nidhi Kline, Timothy L. Wang, Wei You, Zhiying Nguyen, Dustin T. Bing, Kristen Poudyal, Bhavya Johnson, Ginger C. Jackman, Matthew R. Miller, Marsha Steele, Cortney N. Serkova, Natalie J. MacLean, Paul S. Nemenoff, Raphael A. Gitomer, Berenice Chonchol, Michel Nowak, Kristen L. iScience Article Progression of autosomal dominant polycystic kidney disease (ADPKD) is modified by metabolic defects and obesity. Indeed, reduced food intake slows cyst growth in preclinical rodent studies. Here, we demonstrate the feasibility of daily caloric restriction (DCR) and intermittent fasting (IMF) in a cohort of overweight or obese patients with ADPKD. Clinically significant weight loss occurred with both DCR and IMF; however, weight loss was greater and adherence and tolerability were better with DCR. Further, slowed kidney growth correlated with body weight and visceral adiposity loss independent of dietary regimen. Similarly, we compared the therapeutic efficacy of DCR, IMF, and time restricted feeding (TRF) using an orthologous ADPKD mouse model. Only ADPKD animals on DCR lost significant weight and showed slowed cyst growth compared to ad libitum, IMF, or TRF feeding. Collectively, this supports therapeutic feasibility of caloric restriction in ADPKD, with potential efficacy benefits driven by weight loss. Elsevier 2021-12-27 /pmc/articles/PMC8760407/ /pubmed/35059607 http://dx.doi.org/10.1016/j.isci.2021.103697 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Hopp, Katharina Catenacci, Victoria A. Dwivedi, Nidhi Kline, Timothy L. Wang, Wei You, Zhiying Nguyen, Dustin T. Bing, Kristen Poudyal, Bhavya Johnson, Ginger C. Jackman, Matthew R. Miller, Marsha Steele, Cortney N. Serkova, Natalie J. MacLean, Paul S. Nemenoff, Raphael A. Gitomer, Berenice Chonchol, Michel Nowak, Kristen L. Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease |
title | Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease |
title_full | Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease |
title_fullStr | Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease |
title_full_unstemmed | Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease |
title_short | Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease |
title_sort | weight loss and cystic disease progression in autosomal dominant polycystic kidney disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760407/ https://www.ncbi.nlm.nih.gov/pubmed/35059607 http://dx.doi.org/10.1016/j.isci.2021.103697 |
work_keys_str_mv | AT hoppkatharina weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT catenaccivictoriaa weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT dwivedinidhi weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT klinetimothyl weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT wangwei weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT youzhiying weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT nguyendustint weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT bingkristen weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT poudyalbhavya weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT johnsongingerc weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT jackmanmatthewr weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT millermarsha weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT steelecortneyn weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT serkovanataliej weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT macleanpauls weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT nemenoffraphaela weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT gitomerberenice weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT choncholmichel weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease AT nowakkristenl weightlossandcysticdiseaseprogressioninautosomaldominantpolycystickidneydisease |